$CTTH

CTT PHARMACEUTICAL HOLDINGS, INC. purchased $518 of CTTH

CTT PHARMACEUTICAL HOLDINGS, INC. (CEO) purchased 11,500 shares of CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) at $0.04 on 2026-08-20.

Original reporting
SEC EDGAR · CTT PHARMACEUTICAL HOLDINGS, INC.
Published Aug 20, 2026, 2:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CTTH
Neutral
medium confidence
Mentioned
$CTTH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTTHNeutralLow
01

Why it matters

The filing provides a fresh data point on insider activity but the modest size limits trading relevance.

02

Market read

Primary insider purchase disclosed; low materiality.

03

What to watch

CEO's existing large stake may dilute the significance of this incremental buy.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$CTTHNeutralMedium confidence
Context

CEO purchased 11,500 shares for $517.50 in a Form 4 filing.

Expected impact

Limited short-term impact; may provide slight bullish bias.

Evidence & confidence

The transaction is a primary disclosure but the dollar amount is trivial, so market reaction is expected to be muted.

Market effects

Minimal effect on the pharmaceutical sector.

None

None

Counterpoint

The small purchase could be a routine portfolio rebalancing, not a strong endorsement.

Key entities

  • CTT Pharmaceutical Holdings, Inc.

    Issuer of the Form 4 filing.

  • CEO (unnamed)

    Insider executing the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles